CVS will no longer fill prescriptions from telehealth companies Cerebral and Done Health for controlled substances. The pharmacy chain said that, following a review, it had unresolved concerns with both companies. The Wall Street Journal first reported the news.

“We are committed to making mental health services as accessible and convenient as possible. At the same time, it is important that medications are prescribed appropriately,” CVS Health’s executive director of corporate communications Mike DeAngelis told Engadget. 

“We recently conducted a review of certain telehealth companies that prescribe controlled substance medications. As a result of our being unable to resolve concerns we have with Cerebral and Done Health, effective May 26th, 2022, CVS Pharmacy will no longer accept prescriptions for controlled substances issued through these companies.”

The startups have tens of thousands of patients between them, the Journal notes. They have prescribed stimulants such as Adderall for patients with attention-deficit hyperactivity disorder (ADHD). These stimulants are regulated and classed as schedule 2 controlled substances due to the risk of abuse.

Some other pharmacies, such as Walmart and Truepill, previously delayed or declined to fill prescriptions from the two startups. They reportedly had concerns that clinicians at Cerebral and Done were writing too many stimulant prescriptions.

It recently emerged that Cerebral is under investigation by the Department of Justice and the Drug Enforcement Administration. Following that news, the company put prescriptions for ADHD meds for new patients on hold. Cerebral said last week it would stop prescribing most controlled substances for all patients by October. Just two days after that, its board replaced CEO Kyle Robertson.

Along with ADHD, Cerebral says it treats depression, PTSD, anxiety disorders and serious mental illnesses through therapy, counseling and, in some cases, prescriptions. Done focuses on ADHD treatment. 

Before the onset of the COVID-19 pandemic, clinicians were banned from prescribing stimulants without an in-person visit with patients. Those federal rules were loosened in March 2020 for schedule 2 substances, which enabled Cerebral and Done to start offering prescriptions after virtual consultations.

Engadget has contacted Cerebral and Done for comment.

All products recommended by Engadget are selected by our editorial team, independent of our parent company. Some of our stories include affiliate links. If you buy something through one of these links, we may earn an affiliate commission.